- Home
- PNI vs MCRB Comparison
PNI vs MCRB Comparison
Compare PNI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | MCRB |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 71.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PNI | MCRB |
|---|---|---|
| Price | $6.83 | $5.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 73.6K | ★ 86.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.48 | $4.59 |
| 52 Week High | $7.20 | $29.98 |
Technical Indicators
Market Signals| Indicator | PNI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 25.76 | 38.28 |
| Support Level | $6.64 | N/A |
| Resistance Level | $7.06 | $9.53 |
| Average True Range (ATR) | 0.05 | 0.35 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 10.00 | 41.82 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.